2022 World Conference on Lung Cancer (ePosters)-EP07.01-001. Molecular Profiling Predicts Outcomes in Patients With Resected Malignant Pleural Mesothelioma

Pdf Summary

A recent study conducted by researchers at various medical institutes in the United States and Italy has found that molecular profiling can be used to predict outcomes in patients with resected malignant pleural mesothelioma (MPM). MPM is a rare and aggressive cancer with limited treatment options and a poor prognosis. The study retrospectively analyzed tumor samples and blood samples from patients with resected MPM and performed targeted next-generation sequencing to identify genetic mutations. The researchers found that higher tissue and blood tumor mutation burden (TMB), higher median minor allele frequency (MAF), and specific tissue mutations were associated with better disease-free survival (DFS) and overall survival (OS).<br /><br />The study also revealed that MPM tumors have poor mutational landscapes characterized by minute mutations rather than driver mutations. The researchers identified the presence of specific gene mutations, such as KMT2C, PBRM1, and PKHD1, which were associated with poorer outcomes in patients.<br /><br />Although the study had limitations, including a small number of patients, the findings suggest that molecular profiling could be used as a predictive biomarker to identify longer survivors in patients with resected MPM. This opens the door for further research and potential advancements in personalized treatment approaches for MPM patients.<br /><br />The study was approved by the Ethical Committee of the University of Maryland Hospital, and written informed consent was obtained from all patients. The researchers would like to thank the patients, their families, the supporting institutions, and the National Mesothelioma Virtual Registry and Tissue Bank (NMVB) for their contributions to the study.<br /><br />In conclusion, molecular profiling can help predict outcomes in patients with resected MPM, providing valuable information for personalized treatment strategies. Further research with larger sample sizes is needed to validate and expand upon these findings.

Asset Subtitle

Christian Diego Rolfo

Meta Tag

Speaker Christian Diego Rolfo

Topic Mesothelioma, Thymoma, and Other Thoracic Malignancies - Clinical

Keywords

molecular profiling

resected malignant pleural mesothelioma

genetic mutations

tumor mutation burden

minor allele frequency

disease-free survival

overall survival

specific gene mutations

predictive biomarker

personalized treatment approaches